• Independent study completed to explore NUZ-001's effect on survival and autophagy in NSC-34 motor neuron cell line
• NUZ-001 had a small but significant survival effect on TDP-43-mediated cell death following acute treatment
• The survival effect was independent of the activation of autophagy, suggesting an additional pharmacological process may be at play

Neurizon Therapeutics Limited (ASX: NUZ) announced results from an additional independent study carried out in partnership with Professor Trent Woodruff and Dr John Lee's research group at The University of Queensland (UQ). The aim of the study was to investigate the acute effects of NUZ-001 on the survival of mouse NSC-34 motor neurons following exposure to TDP-43 aggregates and link any changes in viability to enhanced autophagy. Preliminary data suggest that NUZ-001 had a small but significant effect on TDP-43-mediated cell death in the mouse MSC-34 motor neuron cell line. Despite enhancing survival, acute treatment with NUZ-001 showed no effect on autophagy markers, suggesting that an additional pharmacological process may be at play. These data also suggest that the neuroprotective effects of NUZ-001 may require repeated exposure providing further insight into its overall biological effects. Future studies will evaluate the effects of NUZ-001 under specific treatment conditions to further elucidate the biological mechanism of action.

Future studies will evaluate the effects of NUZ-001 under specific treatment conditions to further elucidate the biological mechanism of action.